as 07-04-2025 12:30pm EST
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
Founded: | 2015 | Country: | United States |
Employees: | N/A | City: | FREMONT |
Market Cap: | 22.1M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 436.6K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.22 | EPS Growth: | N/A |
52 Week Low/High: | $0.40 - $3.12 | Next Earning Date: | 08-13-2025 |
Revenue: | $508,383 | Revenue Growth: | 1904.43% |
Revenue Growth (this year): | 735.18% | Revenue Growth (next year): | N/A |
ABVC Breaking Stock News: Dive into ABVC Ticker-Specific Updates for Smart Investing
NewMediaWire
11 days ago
NewMediaWire
13 days ago
MT Newswires
19 days ago
NewMediaWire
a month ago
NewMediaWire
a month ago
GOBankingRates
a month ago
GOBankingRates
a month ago
GOBankingRates
a month ago
The information presented on this page, "ABVC ABVC BioPharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.